- Home
- GHI vs AARD Comparison
GHI vs AARD Comparison
Compare GHI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | AARD |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 231.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | GHI | AARD |
|---|---|---|
| Price | $6.46 | $14.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.00 | ★ $30.63 |
| AVG Volume (30 Days) | 155.1K | ★ 219.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 22.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $26,247,399.00 | N/A |
| Revenue This Year | $201.02 | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | $38.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $4.88 |
| 52 Week High | $13.29 | $19.58 |
Technical Indicators
Market Signals| Indicator | GHI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 65.38 |
| Support Level | $6.46 | $14.27 |
| Resistance Level | $6.73 | $16.00 |
| Average True Range (ATR) | 0.28 | 1.07 |
| MACD | 0.08 | 0.52 |
| Stochastic Oscillator | 18.50 | 79.91 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.